Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: ddl who wrote (322)	8/3/2005 12:00:17 PM
From: Pluvia	Read Replies (1) \| Respond to of 377

i've read the Guillermo Torre-Amione chf paper and know it well, along with every other paper published on all aspects of vsgn's research. chf is an interesting market. that said, most researchers note the vsgn chf and paod trials failed to use a number of commonly avaialble diagnostics that would have better evidenced results, or lack of results. i think vsgn did this on purpose as using the better diagnostics would have demonstrated very marginal results. vsgn's problem is 10cc's is not a big enough dose. others can produce a bigger dose... which is just one reason i think vsgn gets leapfrogged... one other thing, the diagnostics used in the chf trial are not impressive, fyi.